当中性粒细胞变得流时:呼吸道疾病中的失调炎症和治疗方面的影响
Yimin Zhu1, Sarmi Sardar1, Jane E Bourke2,3
1Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC 3010, Australia.
ACS pharmacology & translational science
|February 19, 2026
概括
呼吸道中中性粒细胞的积累会导致组织损伤和肺部功能障碍. 针对中性粒细胞失调,为慢性肺部疾病 (如COPD和喘) 提供了新的治疗方法.
科学领域:
- 肺免疫学 肺免疫学
- 天生的免疫反应.
- 炎症性疾病机制 炎症性疾病机制
背景情况:
- 空气道中性质细胞的炎症导致中性质细胞的积累,其特点是延长存活时间,增加亡,并损害了细胞形成.
- 功能失调的中性粒细胞释放血清蛋白酶,导致呼吸道组织破坏,并促进慢性炎症和肺功能障碍的循环.
- 目前对中性恋肺部疾病的治疗方法是普遍的,通常是无效的.
研究的目的:
- 探索中性粒细胞失调和各种肺部疾病的疾病进展之间的复杂关系.
- 突出中性粒细胞在不同肺部疾病中的多样性作用.
- 总结目前针对关键中性粒细胞通路的治疗策略.
主要方法:
- 关于中性粒细胞生物学和失调的最近发现的文献综述.
- 在呼吸道炎症的背景下分析中性粒细胞功能.
- 综合有关治疗目标和临床结果的信息.
主要成果:
- 中性粒细胞在肺中的持久性驱动慢性组织损伤,重塑和炎症,导致渐进的肺功能障碍.
- 中性粒细胞失调与诸如囊性纤维化,慢性肺炎,支气管炎和喘等疾病有关.
- 了解中性粒细胞通路对于开发向疗法至关重要.
结论:
- 针对中性粒细胞失调,为慢性肺部疾病的新型,疾病特异性治疗提供了一个有希望的途径.
- 有效缓解中性粒细胞驱动的炎症可以显著改善肺部疾病患者的临床结果.
- 未来的研究将重点放在关键的中性粒细胞通路上,这可能会彻底改变中性粒细胞肺疾病的管理.
相关概念视频
Asthma-II: Pathophysiology and Classification
4.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.6K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.9K
Asthma: Pathogenesis and Management
1.4K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.4K
Drugs Used in Lower Respiratory Disorders: Overview
1.2K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.2K
Inflammation
62.6K
Overview
62.6K
Antiasthma Drugs: Leukotriene Modifiers
1.9K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.9K


